Universal Beteiligungs und Servicegesellschaft mbH Invests $6.65 Million in Guardant Health, Inc. (NASDAQ:GH)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has acquired a new stake in Guardant Health, purchasing 156,148 shares valued at approximately $6.65 million, which constitutes 0.13% of the company's stock.
• Investment analysts have shown a positive outlook for Guardant Health, with several firms raising their price targets and offering buy ratings, resulting in a consensus rating of "Buy" and an average target price of $54.45.
• Insider trading activity has been notable, with CEO Amirali Talasaz selling over 106,000 shares recently, decreasing his holdings by 4.62%, amidst a broader trend of insiders selling 342,300 shares worth over $17 million in the last 90 days.

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 156,148 shares of the company's stock, valued at approximately $6,652,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.13% of Guardant Health at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. NewEdge Advisors LLC boosted its stake in Guardant Health by 13.5% in the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock worth $59,000 after buying an additional 230 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Guardant Health in the 4th quarter worth approximately $61,000. GF Fund Management CO. LTD. purchased a new stake in shares of Guardant Health in the 4th quarter valued at $79,000. Quantbot Technologies LP purchased a new stake in shares of Guardant Health in the 4th quarter valued at $80,000. Finally, TD Waterhouse Canada Inc. grew its holdings in shares of Guardant Health by 126.2% during the 4th quarter. TD Waterhouse Canada Inc. now owns 2,929 shares of the company's stock valued at $89,000 after purchasing an additional 1,634 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.

Guardant Health Price Performance

NASDAQ:GH traded down $0.15 during mid-day trading on Monday, hitting $44.27. 1,775,727 shares of the company's stock were exchanged, compared to its average volume of 2,256,434. The company has a market cap of $5.48 billion, a PE ratio of -13.06 and a beta of 1.44. Guardant Health, Inc. has a one year low of $20.14 and a one year high of $53.42. The business has a fifty day moving average price of $46.75 and a 200 day moving average price of $44.80.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.08. The company had revenue of $203.47 million for the quarter, compared to the consensus estimate of $189.91 million. During the same period last year, the business earned ($0.46) EPS. The firm's quarterly revenue was up 20.8% on a year-over-year basis. On average, equities analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Barclays boosted their price target on shares of Guardant Health from $55.00 to $60.00 and gave the stock an "overweight" rating in a research note on Thursday, May 1st. Scotiabank reissued an "outperform" rating on shares of Guardant Health in a research note on Monday, May 5th. Evercore ISI upgraded Guardant Health to a "strong-buy" rating in a research report on Monday, July 14th. Mizuho increased their price objective on Guardant Health from $60.00 to $65.00 and gave the company an "outperform" rating in a research note on Friday, June 13th. Finally, Stifel Nicolaus upped their price objective on shares of Guardant Health from $53.00 to $60.00 and gave the company a "buy" rating in a research note on Thursday, May 1st. Twenty research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Guardant Health currently has an average rating of "Buy" and an average target price of $54.45.

Insider Transactions at Guardant Health

In other Guardant Health news, Director Meghan V. Joyce sold 3,337 shares of Guardant Health stock in a transaction on Friday, June 13th. The stock was sold at an average price of $47.22, for a total value of $157,573.14. Following the completion of the sale, the director owned 11,150 shares of the company's stock, valued at approximately $526,503. This trade represents a 23.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Myrtle S. Potter sold 2,626 shares of Guardant Health stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $49.70, for a total value of $130,512.20. Following the completion of the sale, the director owned 18,180 shares of the company's stock, valued at $903,546. The trade was a 12.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 342,300 shares of company stock worth $17,082,238 over the last quarter. Corporate insiders own 6.10% of the company's stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.